Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
In this study in China (n=355), the addition of tislelizumab to chemotherapy (paclitaxel and carboplatin) was associated with improved progression-free survival in patients with advanced squamous non–small-cell lung cancer (7.6 v 5.5 months; p<0.001).
Source:
JAMA Oncology